Opinion|Videos|April 14, 2025
INVICTUS Trial: Ripretinib in Fourth-Line Setting
Experts discuss the key efficacy and safety findings from the INVICTUS trial that established ripretinib in the fourth-line setting, and how the inclusion of ripretinib has influenced their approach to managing patients with heavily pretreated gastrointestinal stromal tumors (GIST).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The INVICTUS trial established ripretinib in the fourth-line setting. Could you review the key efficacy and safety findings from this pivotal study? Please also comment on how ripretinib changed your approach to managing patients with heavily pretreated GIST.
- So we've seen how ripretinib demonstrated significant efficacy in the fourth-line setting in INVICTUS. Building on this success, the
INTRIGUE trial was designed to evaluate ripretinib earlier in the treatment sequence, specifically in the second-line setting compared to standard sunitinib. Before we discuss those data, I'd like to present a case that will help illustrate the challenges of treatment selection after first-line progression and set the stage for our discussion of the INTRIGUE results.
Advertisement
Related to this article
The designation covers QTX3034 plus cetuximab with or without FOLFOX; phase 1 data showed a 25% confirmed ORR with the doublet in CRC and PDAC.
MimiVax and Roswell Park announced phase 2b SURVIVE trial results evaluating the SurVaxM vaccine in newly diagnosed glioblastoma.
Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.
The FDA granted fast track designation to MC001 for pancreatic cancer.
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5